Glenmark Pharmaceuticals, the US subsidiary of Glenmark Pharmaceuticals, is planning to introduce 11 dermatological products in the next one year.
The company has acquired the US marketing rights for a range of clobetasol propionate products, which is used to treat ailments like eczema and psoriasis. It is also dispensed to counter auto-immune presentations such as Alopecia areata (hair loss due to auto-immune diseases) and Lichen planus (auto immune skin nodules).
No comments:
Post a Comment